Physician profile
Michael D Satchell
NPI 1205822806
$16,827.40
in general payments reported to CMS, 2019-2025
54 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,256 · 2020: $2,136 · 2021: $2,728 · 2022: $2,776 · 2023: $2,532 · 2024: $2,246 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,930.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,526.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,314.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $911.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $893.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $878.80 | 2022-2025 | Ingrezza, Ongentys |
| Bayer Healthcare Pharmaceuticals INC. | $849.54 | 2022-2025 | |
| Amgen INC. | $746.66 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $741.11 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $622.71 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $509.64 | 2019-2024 | Verquvo, Capvaxive, Steglatro |
| Lilly USA, LLC | $480.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $415.94 | 2019-2025 | Linzess, Viberzi |
| Abbott Laboratories | $414.85 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $406.77 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $383.37 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Satchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.